AdAlta (1AD) 2017年年度报告「ASX」.pdf

1、FINANCIAL REPORTFOR THE YEAR ENDED 30 JUNE 2017ADALTA LTDABN 92 120 332 925(formerly AdAlta Pty Ltd)AdAlta Limited Annual Report 20172CORPORATE DIRECTORYDIRECTORSDr Paul MacLemanMs Samantha CobbDr James WilliamsMs Elizabeth McCall Dr John ChiplinDr Robert Peach(appointed 14 November 2016)COMPANY SEC

2、RETARYCameron Jones(appointed 31 May 2017)Ian Hobson(resigned 31 May 2017)REGISTERED OFFICEUnit 152 Park DriveBundoora VIC 3083Telephone:+61 3 9479 5159 Email:.au Website:.auSTOCK EXCHANGEAustralian Securities Exchange Limited2 The EsplanadePerth WA 6000ASX CODE1ADSHARE REGISTRYAutomic Registry Serv

3、ices Suite 310,Level 350 Holt StreetSurrey Hills NSW 2010Telephone:1300 288 664Website:.auAUDITORButler Settineri(Audit)Pty Ltd Unit 16,First Floor100 Railway RoadSubiaco WA 6008BANKERSWestpac Banking CorporationSOLICITORSHive Legal Pty LtdLevel 4,50 Market StreetMelbourne VIC 3000 AdAlta Limited An

4、nual Report 20173CONTENTSCHAIRMANS LETTER.4DIRECTORS REPORT.6OPERATING AND FINANCIAL REVIEW.9FINANCIAL YEAR 2017 A YEAR OF MEASURABLE PROGRESS.10INDEPENDENT AUDITORS REPORT.22AdAlta Limited Annual Report 20174CHAIRMANS LETTERIt is my pleasure to open the financial year 2017 annual report looking bac

5、k upon a year where AdAlta achieved some very significant milestones.During the year we made great advances in demonstrating the strength of the AdAlta drug development platform.In addition,the successful listing of the Company on the ASX has brought additional capital,investors and financial market

6、 validation of the products and value creation that AdAlta is working to create.In August of 2016,AdAlta executed a successful listing on the Australian Securities Exchange,closing the fund raising oversubscribed and hence with good aftermarket support.The quality of incoming investors was outstandi